Lingnan Fire-Needle Therapy Improves the Quality of Life in General Population Under the Pandemic of novel coronavirus pneumonia (COVID-19): A Prospective, Randomized Controlled Trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032346

Enrollment

Unknown

Registered

2020-04-26

Start date

2020-04-21

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Intervention group:Lingnan Fire-Needle Therapy

Control:Health and life guidance

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. in line with epidemiological history survey and negative forCOVID-19 RNA screening 2. in line with inclusion criteria and voluntarily receive fire needle treatment 3. Aged 18 to 65 years old; 4. Quality of life score<=37; 5. Voluntary participation in this study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. People who are taking anticoagulant drugs (such as warfarin), or have received other related treatments, may affect the indicators of this study; 2. Pregnant women; 3. Those who cannot tolerate fire needles due to allergies, stress, etc.

Design outcomes

Primary

Measure	Time frame
Quality of life score;	—

Secondary

Measure	Time frame
Mental health score;	—

Countries

China

Contacts

Public ContactGuohua Lin

The First Afflicated Hospital of Guangzhou University of Chinese Medicine

tcmlin-801@163.com+86 13609021435

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026